Haleon PLC Sponsored ADR ( (HLN) ) has shared an announcement.
On April 10, 2025, Haleon PLC announced the purchase of 877,360 ordinary shares for cancellation as part of its share buyback program initiated on March 28, 2025. This transaction aims to reduce the number of shares in circulation, potentially increasing the value of remaining shares and enhancing shareholder value. Following this transaction, Haleon’s registered share capital stands at 9,033,212,761 ordinary shares, with 9,028,132,556 shares holding voting rights. This move is part of Haleon’s strategic financial management to optimize its capital structure and reflects the company’s robust market position in the consumer health sector.
Spark’s Take on HLN Stock
According to Spark, TipRanks’ AI Analyst, HLN is a Outperform.
Haleon’s strong financial performance, characterized by robust cash flow and stable profitability, is a key strength, complemented by positive technical indicators suggesting upward momentum. However, the stock’s valuation appears high, and recent earnings call highlights both opportunities in emerging markets and challenges like FX headwinds and product performance issues. These factors collectively position the stock at a solid yet cautious 73.1 score.
To see Spark’s full report on HLN stock, click here.
More about Haleon PLC Sponsored ADR
Haleon PLC is a global leader in consumer health, focusing on delivering better everyday health with a human touch. The company offers a diverse product portfolio across five major categories: Oral Health, Pain Relief, Respiratory Health, Digestive Health, and Vitamins, Minerals, and Supplements (VMS). Renowned brands under Haleon include Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax, and Centrum, all of which are grounded in trusted science and innovation.
YTD Price Performance: 2.22%
Average Trading Volume: 11,252,476
Technical Sentiment Signal: Buy
Current Market Cap: $41.42B
See more insights into HLN stock on TipRanks’ Stock Analysis page.